Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Lee Herman

Internal Medicine Suwanee, GA Medical Doctor

NPI 1184779027 CMS profile 145136

4365 Johns Creek Parkway, Suite 400, Suwanee, GA 30024

Open in the dashboard

General payments

$13,675

550 records reported · program years 2019–2025

Research payments

$13,549

Paid to them · 9 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$990,360 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Lee Herman of Suwanee, GA is reported in the CMS Open Payments database as having received $13,675 across 550 general payments and $13,549 in research payments paid to them. Separately, studies naming them as principal investigator received $990,360 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

13 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $679 36
2025 Research $3,362 1
2024 General $926 44
2023 General $2,724 74
2023 Research $2,825 3
2022 General $1,559 115
2022 Research $428 1
2021 General $1,559 123
2021 Research $867 1
2020 General $4,520 67
2020 Research $4,490 2
2019 General $1,709 91
2019 Research $1,577 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lee Herman
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Lee Herman were reported at $679. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Lee Herman Internal Medicine median Middle half National median
2019 $1,709 $159 $48–$570 $163
2020 $4,520 $119 $33–$402 $114
2021 $1,559 $135 $37–$521 $132
2022 $1,559 $141 $42–$496 $149
2023 $2,724 $149 $45–$519 $160
2024 $926 $154 $47–$537 $164
2025 $679 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $3,792 97 payments
  2. Bayer HealthCare Pharmaceuticals Inc. $3,090 31 payments
  3. Amgen Inc. $1,172 54 payments
  4. Eli Lilly and Company $598 24 payments
  5. AstraZeneca Pharmaceuticals LP $572 32 payments
  6. GlaxoSmithKline, LLC. $412 18 payments
  7. AbbVie, Inc. $406 24 payments
  8. Lilly USA, LLC $347 22 payments
  9. Kowa Pharmaceuticals America, Inc. $320 76 payments
  10. Esperion Therapeutics, Inc. $317 17 payments
  11. Other $2,649 155 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,817 535 payments
  2. Consulting Fee $3,539 4 payments
  3. Travel and Lodging $1,299 9 payments
  4. Education $21 2 payments
Products named General payments · program years 2019–2025
  1. RYBELSUS $3,173 59 payments
  2. Kerendia $1,931 30 payments
  3. Non-Covered $1,159 1 payment
  4. Ozempic $1,089 69 payments
  5. Repatha $825 38 payments
  6. FARXIGA $444 24 payments
  7. Otezla $439 21 payments
  8. Livalo $320 76 payments
  9. NEXLETOL $317 17 payments
  10. SHINGRIX $292 10 payments
  11. Other $5,611 392 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Eli Lilly and Company $7,647 6 payments
  2. Bayer HealthCare Pharmaceuticals Inc. $5,902 3 payments

Prescribing to Medicare patients

Part D · data year 2024 · 116 drugs

Part D claims

7,078

Median for Internal Medicine: 777

Drug cost

$751,998

Median for Internal Medicine: $73,373

Branded share of claims

17.4%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 60 $79,257
Repatha Sureclick Evolocumab Brand 47 $73,179
Mounjaro Tirzepatide Brand 56 $72,117
Jardiance Empagliflozin Brand 58 $71,568
Januvia Sitagliptin Phosphate Brand 53 $61,378
Farxiga Dapagliflozin Propanediol Brand 35 $50,807
Prolia Denosumab Brand 25 $39,652
Eliquis Apixaban Brand 34 $35,436
Trulicity Dulaglutide Brand 22 $32,306
Kerendia Finerenone Brand 38 $31,090

The 10 drugs with the highest cost, of 116 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 72 billing codes

Paid by Medicare

$291,753

Of which drugs: $44,011

Medicare patients

798

Average age 77

Services billed

9,307

391 women, 407 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 48%
Ischemic heart disease 37%
Diabetes 29%
Chronic kidney disease 23%
Cancer 19%
Atrial fibrillation 17%
Depression 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 24 2,040 $41,867
Injection, methylprednisolone acetate, 1 mg J1010 Office 30 893 $89
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 24 68 $62
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg J7613 Office 12 12 $1

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $146
$146 38 —
UBRELVY
  • AbbVie, Inc. $49
$49 — —
Xelstrym
  • Noven Therapeutics, LLC $41
$41 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $32
$32 24 —
Wegovy
  • Novo Nordisk Inc $29
$29 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

559 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record